

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

August 2018
Volume 21, No. 8

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Drug Update** – Nivolumab Dosing Change
- **Benefit Drug List** – New: UGUAVNIV4, UHNAVIV4, ULUAVNIV4, USMAVNIV4; Deleted: UBRLACEF
- **Cancer Drug Manual** – Revised: Capecitabine, Carfilzomib, Leucovorin, Nivolumab, Rituximab; Editorial Board Update
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: UBRAJTTW, BRAVTW, BRLATWAC, UGUAVNIV4, UHNAVIV4, ULUAVNIV4, USMAVNIV4; Revised: BRAJZOL2, BRAJZOL5, UGOOVBEVG, GOOVCA TR, UGUAVNIV, UGUPABI, UHNAVIV, HNNAVPE, ULUAVNIV, ULYAJBV, ULYBRENTUX, LYGDPR, UMYLDF, MYMPBOR, USMAVNIV; Deleted: UBRLACEF
- **Website Resources and Contact Information**

DRUG UPDATE

NIVOLUMAB DOSING CHANGE

Effective August 1st, all nivolumab-containing protocols and pre-printed orders have been revised to reduce the infusion time to 30 minutes from 60 minutes, as per the recently updated Health Canada-approved drug monograph. Furthermore, BC Cancer has also approved the option of administering nivolumab every 4 weeks in addition to the existing 2-weekly dosing to align with standardized practices across Canada. If a patient had been previously approved for nivolumab treatment by the BC Cancer Compassionate Access Program (CAP), no new CAP approval is required should the physician switch to the 4-weekly treatment schedule.

The BC Cancer-approved nivolumab dosing options and their associated protocols are summarized below:

Dosing Options	Affected Protocols
Nivolumab 3 mg/kg IV every 2 weeks (maximum 240 mg)	UGUAVNIV UHNAVIV ULUAVNIV USMAVNIV
Nivolumab 6 mg/kg IV every 4 weeks (maximum 480 mg)	UGUAVNIV4 UHNAVIV4 ULUAVNIV4 USMAVNIV4

BENEFIT DRUG LIST

NEW PROGRAMS

Effective 01 August 2018, the following treatment programs have been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab	UGUAVNIV4	Restricted
Palliative Therapy for Unresectable, Platinum-refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab	UHNAVIV4	Restricted
Treatment of Advanced Non-Small Cell Lung Cancer using 4-Weekly Nivolumab	ULUAVNIV4	Restricted
Treatment of Unresectable or Metastatic Melanoma using 4-Weekly Nivolumab	USMAVNIV4	Restricted

DELETED PROGRAMS

Effective 01 August 2018, the following treatment program has been deleted from the BC Cancer [Benefit Drug List](#).

Protocol Title	Protocol Code
Therapy for Locally Advanced Breast Cancer using Cyclophosphamide, Epirubicin and Fluorouracil	UBRLACEF

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

Capecitabine Monograph:

- *Interactions* – added proton pump inhibitors to the Interactions table

Carfilzomib Monograph and Chemo Chart:

- *Solution Preparation, Compatibility and Chemo Chart* – added information regarding preparation (recommended needle gauge) and closed system transfer devices

Leucovorin Chemo Chart:

- Added Pfizer brand

CANCER DRUG MANUAL

Nivolumab Monograph:

- *Parenteral Administration table* – added 30-minute infusion time
- *Dosing* – added 6 mg/kg and 480 mg flat rate dosing options

Rituximab Monograph:

- *Supply and Storage, Parenteral Administration table and Dosing* – added information on new 1600 mg subcutaneous formulation; strengthened message on non-interchangeability between products

EDITORIAL BOARD UPDATE

The Cancer Drug Manual (CDM) Editorial Board would like to bid farewell to Terri Gray (RN, BC Cancer – Prince George) as she steps down from the Board to pursue other opportunities. The Board would like to thank Terri for her contributions to the CDM and wishes her all the best for her future.

LIST OF REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
UBRAJTTW	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Therapy for Breast Cancer using Weekly Paclitaxel and Trastuzumab (HERCEPTIN [®])
BRAVTW	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Metastatic Breast Cancer using Weekly Paclitaxel (3 Weeks Out of 4 Weeks Schedule)
BRLATWAC	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Neoadjuvant Therapy for Locally Advanced Breast Cancer using Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide
UGUAVNIV4	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab
UHNAVIV4	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab
ULUAVIV4	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Advanced Non-Small Cell Lung Cancer using 4-Weekly Nivolumab

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
USMAVNIV4	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Unresectable or Metastatic Melanoma using 4-Weekly Nivolumab

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJZOL2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Adjuvant Treatment of Post-Menopausal Women using 3-Monthly Zoledronic Acid
BRAJZOL5	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Adjuvant Treatment of Post-Menopausal Women using 6-Monthly Zoledronic Acid
UGOOVBEVG	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests updated</i>	Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine
GOOVCA TR	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Minor typo corrected</i>	Second-Line Treatment of Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Relapsing after Primary Treatment using Paclitaxel and Carboplatin
UGUAVNIV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institutional name and logo, dosing, tests, infusion time, in-line filter size and references updated</i>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab
UGUPABI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified, and institutional name and logo updated</i>	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer using Abiraterone and Prednisone
UHNAV NIV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institutional name, dosing, infusion time, in-line filter size, return to appointment orders, and references updated</i>	Palliative Therapy for Unresectable, Platinum-refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using Nivolumab
HNNAVPE	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Etoposide infusion time clarified</i>	Treatment of Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Etoposide
ULUAV NIV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institutional name, infusion time, in-line filter size and references updated</i>	Treatment of Advanced Non-Small Cell Lung Cancer using Nivolumab

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
ULYAJBV	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dosing clarified, and institutional name and logo updated</i>	Treatment for Adjuvant Therapy Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma Using Brentuximab Vedotin
ULYBRENTUX	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dosing clarified, and institutional name and logo updated</i>	Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma with Brentuximab Vedotin
LYGDPR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minor formatting change</i>	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Cisplatin (GDP) with Rituximab
UMYLDF	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Minor clarification under treatment</i>	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Lenalidomide with Low-dose Dexamethasone
MYMPBOR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests and dosing clarified</i>	Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib with the Option of Substituting Cyclophosphamide for Melphalan
USMAVNIV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Institutional name and logo, tests, infusion time and in-line filter size updated</i>	Treatment of Unresectable or Metastatic Melanoma using Nivolumab

DELETED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
UBRLACEF	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Therapy for Locally Advanced Breast Cancer using Cyclophosphamide, Epirubicin and Fluorouracil

WEBSITE RESOURCES AND CONTACT INFORMATION

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604-877-6000 x 673028		bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Provincial Professional Practice Nursing			BCCancerPPNAdmin@ehcnet.phsa.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820		rxchemocert@bccancer.bc.ca
BC Cancer-Abbotsford	604-851-4710 Toll Free 877-547-3777		
BC Cancer-Prince George (Centre for the North)	250-645-7300 Toll Free 888-775-7300		
BC Cancer-Surrey	604-930-2098 Toll Free 800-523-2885		
BC Cancer-Kelowna	250-712-3900 Toll Free 888-563-7773		
BC Cancer-Vancouver	604-877-6000 Toll Free 800-663-3333		
BC Cancer-Victoria	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mario de Lemos, PharmD, MSc (Oncol)
 Mark Goodwin, MLIS
 Jagbir Kaur, RN, MN

Caroline Lohrisch, MD
 Judi Piper-Wallace, BSN
 Alison Pow, BSc(Pharm)